US-based Spectrum Pharmaceuticals has begun a Phase II clinical trial of its new pan-HER inhibitor, Poziotinib, for patients with HER2-positive metastatic breast cancer.

The open-label trial will involve around 70 patients who have failed at least two prior HER2-directed therapies.

The company noted that Poziotinib has shown a 60% response rate in Phase I patients with breast cancer who had previously failed multiple lines of treatment, including the HER2-directed therapies.

Poziotinib irreversibly blocks signalling through the epidermal growth factor receptor (EGFR, HER) family of tyrosine-kinase receptors, including HER1, HER2, and HER4.

"We believe Poziotinib has the potential to be the best-in-class pan-HER inhibitor."

It also blocks HER receptor mutations, which inhibits the proliferation of tumour cells that overexpress these receptors.

Spectrum Pharmaceuticals chairman and chief executive officer Rajesh Shrotriya said: "We believe Poziotinib has the potential to be the best-in-class pan-HER inhibitor.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

"The US Phase II trial was designed on learnings from Hanmi’s Phase I studies, as well as the ongoing Phase II breast cancer trial in Korea.

"The target market for HER2-positive agents is large, and we are encouraged by early data showing that Poziotinib could potentially be another treatment option for patients."

It is reported that mutations or overexpression / amplification of EGFR family receptors have been associated with a number of different cancers, including non-small cell lung cancer (NSCLC), breast cancer and gastric cancer.

At present, poziotinib is being evaluated by Hanmi in several mid-stage trials in different solid tumour indications, including HER2-positive breast cancer.

Clinical Trials Arena Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Clinical Trials Arena Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now